<?xml version="1.0" encoding="UTF-8"?>
<p>2′-FdC is considered a viable candidate therapeutic agent against SFTS. Although, 2′-FdC was more effective than favipiravir 
 <italic>in vitro, in vivo</italic> efficacy was less than that of favipiravir (Smee et al., 
 <xref rid="B58" ref-type="bibr">2018</xref>). The administration protocol of 2′-FdC should be considered in future studies.
</p>
